## Mount Sinai -- Clopidogrel Alerts


## IPM PGx Projects

Created: Summer 2013

Revised: Version 3, May 2015

Version 2 effective: September 2014





Created: Summer 2013

Revised: Version 3, May 2015 Version 2 effective: September 2014

## Clopidogrel BPA #1

A. "Clopidogrel Order" PLUS "CYP2C19 \*1/\*2 Genotype"

This patient has been prescribed <u>Clopidogrel</u> and is a <u>CYP2C19</u> Intermediate Metabolizer (\*1/\*2) according to genetic testing. Intermediate Metabolizer status is associated with <u>diminished</u> <u>antiplatelet response</u> to Clopidogrel, and <u>increased risk for adverse cardiovascular events</u> following percutaneous coronary intervention (PCI).

If this patient is undergoing/has undergone PCI and there is no contraindication, consider alternative treatment from the CLIPMERGE SmartSet.

To ignore this advice and proceed with the original order, please select an acknowledgement reason and click Accept.

<u>Click here</u> for further information. The medications in the CLIPMERGE SmartSet may not be appropriate for this patient. Click the Lexi-Comp links in the CLIPMERGE SmartSet for further medication information including indication, dosage and contraindications.

For further assistance: contact us at 646-823-7860 or clipmergeteam@mssm.edu

Icahn School The Charles Bronfman of Medicine at Institute for Personalized Mount Medicine

IPM PGx Projects

Created: Summer 2013

Revised: Version 3, May 2015 Version 2 effective: September 2014

## Clopidogrel BPA #2

B. "Clopidogrel Order" PLUS "CYP2C19 \*2/\*2 Genotype"

This patient has been prescribed <u>Clopidogrel</u> and is a <u>CYP2C19</u> Poor <u>Metabolizer</u> (\*2/\*2) according to genetic testing. Poor <u>Metabolizer</u> status is associated with <u>significantly diminished</u> antiplatelet response to Clopidogrel, and <u>increased risk for adverse cardiovascular events</u> following percutaneous coronary intervention (PCI).

If this patient is undergoing/has undergone PCI and there is no contraindication, consider alternative treatment from the CLIPMERGE SmartSet.

To ignore this advice and proceed with the original order, please select an acknowledgement reason and click Accept.

<u>Click here</u> for further information. The medications in the CLIPMERGE SmartSet may not be appropriate for this patient. Click the Lexi-Comp links in the CLIPMERGE SmartSet for further medication information including indication, dosage and contraindications.

For further assistance: contact us at 646-823-7860 or clipmergeteam@mssm.edu



IPM PGx Projects

Created: Summer 2013

Revised: Version 3, May 2015
Version 2 effective: September 2014